undamentalytics Newsletter
Sign in

Ginkgo Bioworks Holdings, Inc. revenue

Ginkgo Bioworks Holdings, Inc.'s revenue was $170m in fiscal 2025, down 25.1% on the year before. Since fiscal 2019 ($54.2m) it has grown at a compound 21.0% a year. Over the last twelve months it was $112m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue5477314478251227170112
Growth on the year before—+41.5%+309.4%+52.2%−47.4%−9.7%−25.1%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Cell Engineering Revenue $133M 78.0% ▼ 23.7%
Services $37.4M 22.0% ▼ 29.5%
Products $0 0.0% —

From Ginkgo Bioworks Holdings, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Ginkgo Bioworks Holdings, Inc. $112m -46.8% -30.0%
ARS Pharmaceuticals, Inc. $117m 4.1% 711.3%
Arcus Biosciences, Inc. $117m -55.3% -1.1%
Xencor Inc $105m -28.6% -2.5%
Mesoblast LTD $120m 599.2% —
Kymera Therapeutics, Inc. $102m 133.8% 29.7%

Compare with peers

Head to head: DNA vs SPRYDNA vs RCUSDNA vs XNCR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ginkgo Bioworks Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ginkgo Bioworks Holdings, Inc.